Capula Management LTD Corvus Pharmaceuticals, Inc. Transaction History
Capula Management LTD
- $17.1 Billion
- Q1 2025
A detailed history of Capula Management LTD transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Capula Management LTD holds 14,793 shares of CRVS stock, worth $61,834. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,793Holding current value
$61,834% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRVS
# of Institutions
105Shares Held
36.7MCall Options Held
1.37MPut Options Held
338K-
Orbimed Advisors LLC San Diego, CA6.94MShares$29 Million0.69% of portfolio
-
Samlyn Capital, LLC New York, NY4.07MShares$17 Million0.21% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$13.7 Million10.31% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.79MShares$11.7 Million0.02% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$11.2 Million0.14% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $195M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...